- Home
- Publications
- Publication Search
- Publication Details
Title
Present and Future of Allogeneic Natural Killer Cell Therapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 6, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2015-06-03
DOI
10.3389/fimmu.2015.00286
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL
- (2014) L. Oevermann et al. BLOOD
- CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
- (2014) M. K. Gleason et al. BLOOD
- Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
- (2014) W. Leung CLINICAL CANCER RESEARCH
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced Cytotoxicity of Natural Killer Cells following the Acquisition of Chimeric Antigen Receptors through Trogocytosis
- (2014) Fu-Nan Cho et al. PLoS One
- Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice
- (2014) Y. Chu et al. Cancer Immunology Research
- Donor Haplotype B of NK KIR Receptor Reduces the Relapse Risk in HLA-Identical Sibling Hematopoietic Stem Cell Transplantation of AML Patients
- (2014) Ulla Impola et al. Frontiers in Immunology
- Controlling Natural Killer Cell Responses: Integration of Signals for Activation and Inhibition
- (2013) Eric O. Long et al. Annual Review of Immunology
- Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
- (2013) H. E. Kohrt et al. BLOOD
- A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
- (2013) Y.-H. Chang et al. CANCER RESEARCH
- The effect of alloferon on the enhancement of NK cell cytotoxicity against cancer via the up-regulation of perforin/granzyme B secretion
- (2013) Seyeon Bae et al. IMMUNOBIOLOGY
- Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling
- (2013) Erik Wennerberg et al. INTERNATIONAL JOURNAL OF CANCER
- Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation
- (2013) Wai-Hang Leung et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
- (2013) J Chu et al. LEUKEMIA
- Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
- (2013) Hua Jiang et al. Molecular Oncology
- Generation and Preclinical Characterization of a Fc-optimized GITR-Ig Fusion Protein for Induction of NK Cell Reactivity Against Leukemia
- (2013) Benjamin Joachim Schmiedel et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
- (2013) Nina Shah et al. PLoS One
- Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
- (2013) Ashley Mentlik James et al. Frontiers in Immunology
- A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
- (2012) N. Vey et al. BLOOD
- A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
- (2012) D. M. Benson et al. BLOOD
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
- (2012) Ariane Thielens et al. CURRENT OPINION IN IMMUNOLOGY
- Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells
- (2012) Roberto Bellucci et al. JOURNAL OF CLINICAL INVESTIGATION
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- CS1-Directed Monoclonal Antibody Therapy for Multiple Myeloma
- (2012) Don M. Benson et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
- (2012) M. K. Gleason et al. MOLECULAR CANCER THERAPEUTICS
- HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1
- (2012) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies
- (2012) Philippe Moreau SEMINARS IN HEMATOLOGY
- Natural killer cells: a review of manufacturing and clinical utility
- (2012) Scott A. Koepsell et al. TRANSFUSION
- Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
- (2011) S. Platonova et al. CANCER RESEARCH
- 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia
- (2011) Corina Buechele et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity
- (2011) Kory L. Alderson et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
- (2011) Ruth Esser et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)
- (2011) C Buechele et al. LEUKEMIA
- Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
- (2011) Jan Spanholtz et al. PLoS One
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
- (2010) S. Cooley et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer
- (2010) Eleni G. Iliopoulou et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients
- (2010) Uwe Siegler et al. CYTOTHERAPY
- A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer
- (2010) Melissa A. Geller et al. CYTOTHERAPY
- NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
- (2010) Jeffrey E. Rubnitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Inhibitory Killer Immunoglobulin Receptor (KIR) Gene Mismatches and KIR Haplotype B Donors after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation
- (2009) Heather J. Symons et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro
- (2009) M. Krusch et al. JOURNAL OF IMMUNOLOGY
- Natural killer cell-based immunotherapy in cancer: current insights and future prospects
- (2009) T. Sutlu et al. JOURNAL OF INTERNAL MEDICINE
- Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses
- (2008) William H.D. Hallett et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation
- (2008) L. Vago et al. BLOOD
- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
- (2008) S. Cooley et al. BLOOD
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL
- (2008) W. Jiang et al. CYTOTHERAPY
- Natural killer cell–directed therapies: moving from unexpected results to successful strategies
- (2008) Magali Terme et al. NATURE IMMUNOLOGY
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now